A PHASE II, OPEN-LABEL, MULTICENTER, MASTER PROTOCOL TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL STUDY INTERVENTIONS AND COMBINATIONS IN PARTICIPANTS WITH COLORECTAL CANCER (CANTOR)

Registry ID

D798VC00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA AB

Start date

2025-07-18

Last update

2025-01-16

Conditions

• COLORECTAL CANCER

Related clinical trials

• A RANDOMIZED, OPEN LABEL, 3-ARM PHASE 3 STUDY OF PRECEMTABART TOCENTECAN WITH OR WITHOUT BEVACIZUMAB COMPARED TO TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB IN PARTICIPANTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (PROCEADE-CRC-03)
• A RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TWO DOSE LEVELS OF ONO-4578 WITH OPDIVO® IN COMBINATION WITH MFOLFOX6 AND BEVACIZUMAB VERSUS STANDARD OF CARE FOR FIRST-LINE TREATMENT OF NON-MSI-H/DMMR, PD-L1 POSITIVE ADVANCED COLORECTAL CANCER
• SAFELY OPTIMIZING BODY WEIGHT WITH MIFOMELATIDE (TCMCB07) IN PATIENTS WITH NEWLY DIAGNOSED COLORECTAL CANCER (CRC) OR PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) UNDERGOING CHEMOTHERAPY
• PHASE 3 MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF SOTORASIB, PANITUMUMAB AND FOLFIRI VERSUS FOLFIRI WITH OR WITHOUT BEVACIZUMAB-AWWB FOR TREATMENT-NAÏVE SUBJECTS WITH METASTATIC COLORECTAL CANCER WITH KRAS P.G12C MUTATION (CODEBREAK 301)
• A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY OF AMIVANTAMAB AND MFOLFOX6 OR FOLFIRI VERSUS CETUXIMAB AND MFOLFOX6 OR FOLFIRI AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH KRAS/NRAS AND BRAF WILD-TYPE UNRESECTABLE OR METASTATIC LEFT-SIDED COLORECTAL CANCER
• PHASE I OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, DOSIMETRY, AND PRELIMINARY ACTIVITY OF [177LU]LU-NNS309 IN PATIENTS WITH PANCREATIC, LUNG, BREAST AND COLORECTAL CANCERS

View on source registry